August 6, 2019

Rajendra Ketkar
President and Chief Executive Officer
Arcadia Biosciences, Inc.
202 Cousteau Place, Suite 105
Davis, CA 95618

       Re: Arcadia Biosciences, Inc.
           Registration Statement on Form S-1
           Filed July 26, 2019
           File No. 333-232858

Dear Mr. Ketkar:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Form S-1

Description of Our Capital Stock, page 5

1.     Refer to Article X, Paragraph F of your Amended and Restated Certificate
of
       Incorporation, which identifies the Court of Chancery of the State of
Delaware as the
       exclusive forum for certain litigation, including "any derivative
action." Please describe
       here the exclusive forum provision and disclose whether this provision
applies to actions
       arising under the Securities Act or Exchange Act. We note in this regard
that Section 27
       of the Exchange Act creates exclusive federal jurisdiction over all
suits brought to enforce
       any duty or liability created by the Exchange Act or the rules and
regulations thereunder,
       and Section 22 of the Securities Act creates concurrent jurisdiction for
federal and state
       courts over all suits brought to enforce any duty or liability created
by the Securities Act
       or the rules and regulations thereunder. To the extent this provision
applies to claims
 Rajendra Ketkar
Arcadia Biosciences, Inc.
August 6, 2019
Page 2
      under the Securities Act, please add a risk factor describing the
attendant risks, and state
      in the prospectus that there is uncertainty whether a court would enforce
the provision and
      that investors cannot waive compliance with the federal securities laws
and the rules and
      regulations thereunder.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact J. Nolan McWilliams, Attorney-Advisor, at (202) 551-3217
or Laura
Nicholson, Special Counsel, at (202) 551-3584 with any questions you may have.



                                                            Sincerely,
FirstName LastNameRajendra Ketkar
                                                            Division of
Corporation Finance
Comapany NameArcadia Biosciences, Inc.
                                                            Office of
Transportation and Leisure
August 6, 2019 Page 2
cc:       Mike DeAngelis, Esq.
FirstName LastName